The 2019 Q3 biotech and pharmaceutical transactions were defined by an active M&A market as deal value increased across all categories when compared to the ...
The 2019 Q2 biotech and pharmaceutical transactions were defined by an active IPO summer market as deal value increased across all categories when compared to ...
Background An established, biomedical research facility was looking to enter into an agreement with a hospital organization which would absorb the research institute in exchange ...
Background A pharmaceutical company, in the midst of a Phase III clinical trial, was considering a variety of strategic and financing alternatives as it prepared ...
The 2019 Q1 biotech and pharmaceutical transactions have come to end, and the initial results showcase some stark differences when compared to the first quarter ...
Biotechnology companies face unique challenges when it comes to understanding the value of their assets. During the early stages of development, an extraordinary level of ...
Biotech and Life Sciences: Q3 2019 Summary